Cargando…
COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting
Since the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19-free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vacc...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465974/ https://www.ncbi.nlm.nih.gov/pubmed/37644838 http://dx.doi.org/10.1098/rspb.2023.1437 |
_version_ | 1785098783777882112 |
---|---|
author | Conway, Eamon Walker, Camelia R. Baker, Christopher Lydeamore, Michael J. Ryan, Gerard E. Campbell, Trish Miller, Joel C. Rebuli, Nic Yeung, Max Kabashima, Greg Geard, Nicholas Wood, James McCaw, James M. McVernon, Jodie Golding, Nick Price, David J. Shearer, Freya M. |
author_facet | Conway, Eamon Walker, Camelia R. Baker, Christopher Lydeamore, Michael J. Ryan, Gerard E. Campbell, Trish Miller, Joel C. Rebuli, Nic Yeung, Max Kabashima, Greg Geard, Nicholas Wood, James McCaw, James M. McVernon, Jodie Golding, Nick Price, David J. Shearer, Freya M. |
author_sort | Conway, Eamon |
collection | PubMed |
description | Since the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19-free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vaccines in early 2021, the national government sought to transition from a state of minimal incidence and strong suppression activities to one of high vaccine coverage and reduced restrictions but with still-manageable transmission. This transition is articulated in the national ‘re-opening’ plan released in July 2021. Here, we report on the dynamic modelling study that directly informed policies within the national re-opening plan including the identification of priority age groups for vaccination, target vaccine coverage thresholds and the anticipated requirements for continued public health measures—assuming circulation of the Delta SARS-CoV-2 variant. Our findings demonstrated that adult vaccine coverage needed to be at least 60% to minimize public health and clinical impacts following the establishment of community transmission. They also supported the need for continued application of test–trace–isolate–quarantine and social measures during the vaccine roll-out phase and beyond. |
format | Online Article Text |
id | pubmed-10465974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104659742023-08-31 COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting Conway, Eamon Walker, Camelia R. Baker, Christopher Lydeamore, Michael J. Ryan, Gerard E. Campbell, Trish Miller, Joel C. Rebuli, Nic Yeung, Max Kabashima, Greg Geard, Nicholas Wood, James McCaw, James M. McVernon, Jodie Golding, Nick Price, David J. Shearer, Freya M. Proc Biol Sci Biological Applications Since the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19-free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vaccines in early 2021, the national government sought to transition from a state of minimal incidence and strong suppression activities to one of high vaccine coverage and reduced restrictions but with still-manageable transmission. This transition is articulated in the national ‘re-opening’ plan released in July 2021. Here, we report on the dynamic modelling study that directly informed policies within the national re-opening plan including the identification of priority age groups for vaccination, target vaccine coverage thresholds and the anticipated requirements for continued public health measures—assuming circulation of the Delta SARS-CoV-2 variant. Our findings demonstrated that adult vaccine coverage needed to be at least 60% to minimize public health and clinical impacts following the establishment of community transmission. They also supported the need for continued application of test–trace–isolate–quarantine and social measures during the vaccine roll-out phase and beyond. The Royal Society 2023-08-30 2023-08-30 /pmc/articles/PMC10465974/ /pubmed/37644838 http://dx.doi.org/10.1098/rspb.2023.1437 Text en © 2023 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited. |
spellingShingle | Biological Applications Conway, Eamon Walker, Camelia R. Baker, Christopher Lydeamore, Michael J. Ryan, Gerard E. Campbell, Trish Miller, Joel C. Rebuli, Nic Yeung, Max Kabashima, Greg Geard, Nicholas Wood, James McCaw, James M. McVernon, Jodie Golding, Nick Price, David J. Shearer, Freya M. COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title | COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title_full | COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title_fullStr | COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title_full_unstemmed | COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title_short | COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
title_sort | covid-19 vaccine coverage targets to inform reopening plans in a low incidence setting |
topic | Biological Applications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465974/ https://www.ncbi.nlm.nih.gov/pubmed/37644838 http://dx.doi.org/10.1098/rspb.2023.1437 |
work_keys_str_mv | AT conwayeamon covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT walkercameliar covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT bakerchristopher covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT lydeamoremichaelj covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT ryangerarde covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT campbelltrish covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT millerjoelc covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT rebulinic covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT yeungmax covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT kabashimagreg covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT geardnicholas covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT woodjames covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT mccawjamesm covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT mcvernonjodie covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT goldingnick covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT pricedavidj covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting AT shearerfreyam covid19vaccinecoveragetargetstoinformreopeningplansinalowincidencesetting |